Psychosocial characteristics of individuals with non-stage IV melanoma

被引:73
|
作者
Trask, PC
Paterson, AG
Hayasaka, S
Dunn, RL
Riba, M
Johnson, T
机构
[1] Univ Michigan, Behav Med Program, Ann Arbor, MI 48108 USA
[2] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Otolaryngol, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA
[6] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA
关键词
D O I
10.1200/JCO.2001.19.11.2844
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Melanoma is the fastest growing solid tumor among men and women and accounts for 79% of skin cancer-related deaths. Research has identified that distress is frequently associated with a diagnosis of cancer and may slow treatment-seeking and recovery, increasing morbidity and even mortality through faster disease course. Given that the 5-year survival rates for individuals with melanoma are determined primarily by the depth and extent of spread, distress that interferes with seeking treatment has the potential to be life-threatening. Patients and Methods: The current study was designed to identify levels of distress present in individuals seeking treatment at a large, Midwestern, multidisciplinary melanoma clinic. It also focused on determining the quality of life, level of anxiety, and coping strategies used by individuals with melanoma before treatment. Given that the course of treatment and outcome for patients with stage IV disease is vastly different from that of patients with stages I to III disease, they were excluded from the study. Results: Results indicated that most individuals who are presenting to a melanoma clinic do not report a clinically significant level of distress. However, there is some variability in this, with 29% of patients reporting moderate to high levels of distress. Moreover, analyses suggest that distressed individuals are more likely to use maladaptive coping strategies, such as escape-avoidance coping, and to have poorer quality of life. Conclusion: Although most individuals do not present with significant levels of distress, a significant minority are distressed and rely more heavily on coping strategies that do not benefit them. Such individuals would likely benefit most from psychological intervention.
引用
收藏
页码:2844 / 2850
页数:7
相关论文
共 50 条
  • [21] Role of Surgery in Stage IV Melanoma
    O'Neill, Conor H.
    McMasters, Kelly M.
    Egger, Michael E.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2020, 29 (03) : 485 - +
  • [22] The cost of unresectable stage III or stage IV melanoma in Italy
    Maio, Michele
    Ascierto, Paolo
    Testori, Alessandro
    Ridolfi, Ruggero
    Bajetta, Emilio
    Queirolo, Paola
    Guida, Michele
    Romanini, Antonella
    Chiarion-Sileni, Vanna
    Pigozzo, Jacopo
    Di Giacomo, Anna Maria
    Calandriello, Mario
    Didoni, Guido
    van Baardewijk, Marck
    Konto, Cyril
    Lucioni, Carlo
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2012, 31
  • [23] The cost of unresectable stage III or stage IV melanoma in Italy
    Michele Maio
    Paolo Ascierto
    Alessandro Testori
    Ruggero Ridolfi
    Emilio Bajetta
    Paola Queirolo
    Michele Guida
    Antonella Romanini
    Vanna Chiarion-Sileni
    Jacopo Pigozzo
    Anna Maria Di Giacomo
    Mario Calandriello
    Guido Didoni
    Marck van Baardewijk
    Cyril Konto
    Carlo Lucioni
    Journal of Experimental & Clinical Cancer Research, 31
  • [24] Palliative therapy of stage IV malignant melanoma
    Freise, J.
    Schadendorf, D.
    ONKOLOGE, 2009, 15 (08): : 767 - +
  • [25] Laparoscopy for Stage IV Melanoma in Two Organs
    Kasza, Jason
    Espinel, Francisco
    Khambaty, Fatima
    Bashir, Showkat
    Brody, Fred
    SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES, 2010, 20 (04): : 295 - 297
  • [26] The role of surgery in treatment of stage IV melanoma
    Young, Shawn E.
    Martinez, Steve R.
    Essner, Richard
    JOURNAL OF SURGICAL ONCOLOGY, 2006, 94 (04) : 344 - 351
  • [27] Rituximab as a therapeutic Option for Melanoma Stage IV
    Schiller, M.
    Bender, C.
    Enk, A.
    Hassel, J. C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 46 - 46
  • [28] The value of metastasectomy in stage IV cutaneous melanoma
    Wollina, Uwe
    Brzezinski, Piotr
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2019, 169 (13-14) : 331 - 338
  • [29] Biomarkers in melanoma: Stage III and IV disease
    Linette, GP
    Carlson, JA
    Slominski, A
    Mihm, MC
    Ross, JS
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2005, 5 (01) : 65 - 74
  • [30] Sequential targeted and immunotherapies in stage IV melanoma
    Amaral, T. M. S.
    Nolinski, J.
    Niessner, H.
    Sinnberg, T.
    Seeber, O.
    Sanchez, S.
    Keim, U.
    Thomas, I.
    Meiwes, A.
    Koechel, A.
    Forschner, A.
    Leiter, U.
    Flatz, L.
    Eigentler, T.
    Garbe, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S875 - S875